Clinical trials: Sclerosis
Multiple Sclerosis
Hand Grip Strength Correlates Strongly With Weekly Working Hours - the Importance of Upper Limb Function in Multiple Sclerosis
Multiple sclerosis (MS) as leading cause of non-traumatic neurological disability in young adults has additionally to the individual's burden of disease a significant influence on their ability to work.
- Trial name
- NCT07889271
- Testing
- hand grip strength
- Where
- Austria
- Volunteers
- 300 people
- Sponsor
- Salzburger Landeskliniken
Multiple Sclerosis
Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide information about the level of activity and progression of Multiple Sclerosis at different stages and landmarks of the disease.
- Trial name
- NeurofilMS (NCT03981003)
- Testing
- Blood sample
- Where
- 28 sites in France, Martinique
- Volunteers
- 1,150 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Amyotrophic Lateral Sclerosis
Regulatory T Cells for Amyotrophic Lateral Sclerosis
Phase 1 Safety Run-in Study of 6 patients followed by Phase 1b Randomized, Double Blind, Placebo Control Trial of CK0803, neurotropic, allogeneic, umbilical cord blood derived T regulatory (Treg) cells in additional 60 patients…
- Trial name
- REGALS (NCT05695521)
- Testing
- CK0803, Excipient
- Where
- 3 sites in United States
- Volunteers
- 66 people
- Sponsor
- Cellenkos, Inc.
Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- NCT06978647
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 12 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Systemic Sclerosis (SSc), Inflammatory Myopathy
- Trial name
- NCT07104721
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Multiple Sclerosis
Motor Imagery and Action Observation for Gait Function in MS
This study will investigate whether mentally simulating walking movements while watching others walk can improve walking performance in individuals with Multiple Sclerosis (MS).
- Trial name
- NCT07137624
- Testing
- Action Observation + Motor Imagery, Nature Video
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Hacettepe University
Neurological Disorder, ALS (Amyotrophic Lateral Sclerosis)
INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study
INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study
- Conditions
- Neurological Disorder, ALS (Amyotrophic Lateral Sclerosis), Motor Neuron Disease, ALS - Amyotrophic Lateral Sclerosis
- Trial name
- NCT07543367
- Testing
- Stentrode
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Synchron, Inc.
Multiple Sclerosis
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Background: In people with multiple sclerosis (MS), brain and cerebrospinal fluid (CSF) biomarkers indicate inflammation or disease. Researchers want to see if 4 drugs given alone or combined affect MS biomarkers.
- Trial name
- NCT03109288
- Testing
- Cilostazol, Leucovorin, Pirfenidone
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy…
- Conditions
- Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- BEAT-MS (NCT04047628)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
- Where
- 23 sites in United States
- Volunteers
- 156 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms
In this study, researchers will learn more about the effects of a drug called tofersen, also known as BIIB067 and QALSODY®, in adults with amyotrophic lateral sclerosis (ALS) who have a superoxide dismutase 1 (SOD1) gene…
- Trial name
- ATLAS (NCT04856982)
- Testing
- Tofersen
- Where
- 32 sites in United States, Australia and 12 more
- Volunteers
- 158 people
- Sponsor
- Biogen
Multiple Sclerosis
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for MS
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of multiple sclerosis
- Trial name
- NCT05003388
- Testing
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells
- Where
- 2 sites in United States, Greece
- Volunteers
- 15 people
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
Systemic Sclerosis
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Systemic Sclerosis
- Trial name
- NCT05016804
- Testing
- AlloRx
- Where
- 2 sites in Antigua and Barbuda, Argentina
- Volunteers
- 20 people
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
Multiple Sclerosis, Fibromyalgia
Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain
The purpose of this study is to to explore the safety and efficacy of the EXOPULSE Mollii suit, a full-body electrostimulation suit, for individuals with neurological or neuromuscular conditions that cause spasticity…
- Conditions
- Multiple Sclerosis, Fibromyalgia, Neurologic Disorder, Neuromuscular Disorders
- Trial name
- NCT07132775
- Testing
- Active full-body stimulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Shirley Ryan AbilityLab
Stroke, PARKINSON DISEASE (Disorder)
Objective Longitudinal Monitoring of Postural Stability and Gait During Neurorehabilitation: Clinical Application of Instrumented Posturography and Three-Dimensional Motion Analysis
Nowadays, stroke is one of the most common leading causes of death in many countries. As the number of stroke patients is increasing, even in younger age groups, there is an increasing need to improve their rehabilitation.
- Conditions
- Stroke, PARKINSON DISEASE (Disorder), Multiple Sclerosis
- Trial name
- NCT07411664
- Testing
- Stroke posturo/3D group, Parkinson posturo/3D group, Multiple sclerosis posturo/3D group
- Where
- Hungary
- Volunteers
- 151 people
- Sponsor
- Somogy Megyei Kaposi Mór Teaching Hospital
Multiple Sclerosis
A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and Japan
This study aims to evaluate the real-world persistence and adherence to ofatumumab (OMB) treatment in adult patients with relapsing multiple sclerosis (RMS).
- Trial name
- NCT07821411
- Where
- Switzerland
- Volunteers
- 5,000 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System
A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).
The main purpose of this study in participants with Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS) is to test the safety of different doses and to determine the amount of LY3873862 that gets into the bloodstream and how…
- Trial name
- NCT07883590
- Testing
- LY3873862, CYP450 Drug Cocktail
- Where
- 4 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Amyotrophic Lateral Sclerosis
Impact of the Combined Treatment of Liposomed Polyphenols With G04CB02 on the ALS Patients
Amyotrophic lateral sclerosis (ALS) is a disease of an inflammatory nature, which causes progressive muscle weakness associated with cognitive and behavioural disorders.
- Trial name
- NCT04654689
- Testing
- Liposomed polyphenols resveratrol and curcumin, Isocaloric Diet, G04CB02
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- Fundación Universidad Católica de Valencia San Vicente Mártir
Multiple Sclerosis, Spasticity, Muscle
Pilot Investigation to Evaluate FlowOx2.0™ for Experimental Treatment of Spasticity
This is a descriptive, prospective, non-controlled clinical investigation to be conducted on approximately 10 enrolled subjects at one site at Haukeland University Hospital in Bergen, Norway.
- Conditions
- Multiple Sclerosis, Spasticity, Muscle, Pain
- Trial name
- FlowOx-MS (NCT04904016)
- Testing
- FlowOx™
- Where
- Norway
- Volunteers
- 10 people
- Sponsor
- Otivio AS
Multiple Sclerosis, Spasticity, Muscle
Performance and Long-term Safety of FlowOx2.0™ in Patients With Multiple Sclerosis - Impact on Spasticity and Pain
The study is a 4-week double-blind, randomized, controlled, parallel design investigation to investigate the impact of intermittent negative pressure on spasticity and pain in people with multiple sclerosis (pwMS).
- Conditions
- Multiple Sclerosis, Spasticity, Muscle, Pain, Chronic
- Trial name
- FO-NP002 (NCT05562453)
- Testing
- FlowOx 2.0
- Where
- Sweden
- Volunteers
- 56 people
- Sponsor
- Otivio AS
Multiple Sclerosis, Spasticity, Muscle
Performance and Long-term Safety of FlowOx2.0™, Multiple Sclerosis, Spasticity and Pain
This study is based on a 4-week double-blind, randomized, controlled, parallel design investigation to investigate the impact of intermittent negative pressure on spasticity and pain in people with multiple sclerosis (pwMS)…
- Conditions
- Multiple Sclerosis, Spasticity, Muscle, Pain
- Trial name
- NCT05598736
- Testing
- FlowOx 2.0
- Where
- Norway
- Volunteers
- 58 people
- Sponsor
- Otivio AS
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.